title: [Sialic acid concentrations in blood samples as well as in cyst and peritoneal fluid in patients with ovarian cysts and cystic ovarian tumors].
abstract: It should be solved the question if the estimation of the TSA-concentrations in various body fluids of patients with ovarian tumour like conditions (n = 11), and benign (n = 28) and malignant (n = 25) cystic ovarian tumours can be used as a tumour marker with an additional clinical information. The determination of the concentrations were carried out in blood sera, cyst and peritoneal fluids. The periodate-thiobarbituric acid-assay was used to measure the TSA-contents. The sensitivity of pre-therapy TSA-concentrations in serum for malignant cystic ovarian tumours is 0.59 at a prevalence of 0.55; the specificity has a value of 0.79. There is no improvement of clinical validity through a pre-therapy TSA/total protein (TP)-ratio in serum (sensitivity 0.41; specificity 0.71). There are no useful clinical data of simultaneous estimation in serum, tumour cystic and peritoneal fluids of the same patient.
authors.affiliation: Frauenklinik des Bezirkskrankenhauses, Wismar, Bundesrepublik Deutschland.
authors.forename: R R
authors.initials: RR
authors.lastname: Strache
authors.forename: H H
authors.initials: HH
authors.lastname: Büttner
authors.forename: P M
authors.initials: PM
authors.lastname: Göcze
authors.forename: V
authors.initials: V
authors.lastname: Briese
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D001826:Body Fluids / Q000737:chemistry*; D003536:Cystadenocarcinoma / Q000737:chemistry; D005260:Female; D006801:Humans; D008875:Middle Aged; D010048:Ovarian Cysts / Q000737:chemistry*; D010051:Ovarian Neoplasms / Q000737:chemistry*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D012794:Sialic Acids / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D012794:Sialic Acids
vernacular_title: Sialinsäure-Konzentrationen in Serumproben sowie Zysten- und Peritonealflüssigkeiten bei Patientinnen mit Ovarialzysten und zystischen Ovarialtumoren.